Cardiff Oncology Inc (NASDAQ:CRDF) does about 1.18M shares in volume on a normal day but saw 1075821 shares change hands in the recent trading day. The company now has a market cap of 212.88M USD. Its current market price is $3.2, marking an increase of 1.27% compared to the previous close of $3.16. The 52 week high reached by this stock is $5.64 whilst the lowest price level in 52 weeks is $2.01.
The consensus objective for the share price is $11.10, suggesting that the stock has a potential upside of 71.17% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 24, 2025 when Jefferies initiated the stock to “Hold” and issued a price target of $3.50.
The current price level is -9.46%, 3.47%, and -2.91% away from its SMA20, SMA50, and SMA200 respectively, with the CRDF price moving below the 50-day SMA on current market day. Cardiff Oncology Inc (CRDF) stock is down -17.10% over the week and 11.11% over the past month. Its price is 31.15% year-to-date and -26.27% over the past year.
To reach the target analysts have set, the stock logically needs to grow 71.17 percent from here.
The company has a return on investment of -68.35% and return on equity of -74.15%. The beta has a value of 1.56. Price to book ratio is 3.00 and price to sales ratio is 360.81.
